凱萊英(002821.SZ)：擬攜手高瓴等增資子公司 將其打造為全球CDMO領域的領軍企業
格隆匯3月25日丨凱萊英(002821.SZ)公佈，為促進公司大分子藥物、抗體偶聯藥物、細胞基因治療藥物以及mRNA藥物等在內的CDMO業務發展，滿足子公司上海凱萊英生物技術發展有限公司(“凱萊英生物技術發展”、“目標公司”)後續資本性支出及運營支出的資金需求，公司、公司董事長HAO HONG、凱萊英生物技術發展、上海凱萊英生物技術有限公司(“凱萊英生物”，截至公吿日為公司的全資附屬公司，並將根據投資協議於首筆增資截止日期或之前成為目標公司全資附屬公司)擬與天津海河凱萊英生物醫藥產業創新投資基金(有限合夥)(“海河凱萊英基金”)、蘇州高瓴祈睿醫療健康產業投資合夥企業(有限合夥)(“高瓴祈睿”)、珠海岱恆股權投資合夥企業(有限合夥)(“珠海岱恆”)、凱萊同心(天津)企業管理諮詢合夥企業(有限合夥)(“凱萊同心”，持股平台)共同簽署《投資協議》。
(公司、HAOHONG、海河凱萊英基金、高瓴祈睿、珠海岱恆、凱萊同心以下合稱“投資方”，目標公司、凱萊英生物和凱萊英醫藥合稱為“保證方”，珠海岱恆與高瓴祈睿合稱“高瓴”)
按照《投資協議》約定的條款與條件，各投資方在目標公司完成對凱萊英生物的全資收購後，對目標公司進行投資並認購目標公司的新增註冊資本。各投資方將按照《投資協議》約定分期向目標公司合計增資不超過約25.34億元人民幣，其中公司對目標公司最大出資額為16.6億元人民幣，在各方均完成首筆增資交易後，凱萊英醫藥對目標公司的持股比例從100%變更為83%。
公司攜手高瓴和海河凱萊英基金，各方擬共同出資將目標公司打造成為全球生物藥及先進療法合同研發生產服務(CDMO)領域的領軍企業，以高水平一站式的專業化研發生產服務，撬動迅速增長的海內外生物藥及先進療法CDMO市場。目標公司未來將定位成為凱萊英醫藥集團中包括大分子藥物、抗體偶聯藥物、細胞基因治療藥物以及mRNA藥物等在內的獨家合同研發生產服務(CDMO)企業。各方也將依託各自領域的資源優勢在行業生態領域以及資本市場領域展開全面深入的戰略合作。
此次目標公司通過增資擴股方式引入外部投資者，符合其未來發展戰略。此次增資有利於增強其資金實力，滿足其後續資本性支出及運營支出的資金需求，提升其整體競爭力，促進公司CDMO業務的發展。此次交易不會影響公司合併報表範圍，交易完成後，公司仍是凱萊英生物技術發展的控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
